Improving Treg therapy to manage anti-drug antibodies in hemophilia treatment
Optimizing precision Treg therapy to control anti-drug antibodies
This study is looking at a new way to help people with hemophilia by improving a type of therapy that can calm down the immune system's unwanted reactions to certain medications, making treatments safer and more effective for you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-11059632 on NIH RePORTER |
What this research studies
This research aims to enhance regulatory T cell (Treg) therapies to effectively suppress anti-drug antibody (ADA) responses in patients receiving biotherapeutics, particularly for hemophilia. The approach involves engineering synthetic receptors that can specifically target and suppress unwanted immune responses while minimizing off-target effects. By utilizing a novel synthetic T cell receptor fusion construct (TRuC), the study seeks to improve the efficacy and safety of Treg therapies, which have shown promise in preliminary models. Patients may benefit from a more effective treatment that reduces complications associated with ADA responses.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with hemophilia who are undergoing treatment with clotting factor replacement therapies.
Not a fit: Patients who do not have hemophilia or are not receiving biotherapeutic treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for hemophilia patients, reducing the risk of adverse immune reactions to necessary therapies.
How similar studies have performed: Previous research has successfully utilized engineered T cell therapies in other contexts, such as CAR T cells for blood cancers, indicating potential for success in this novel application.
Where this research is happening
Indianapolis, United States
- Indiana University Indianapolis — Indianapolis, United States (Active)
Researchers
- Principal investigator: Biswas, Moanaro — Indiana University Indianapolis
- Study coordinator: Biswas, Moanaro
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.